Replimune Group, Inc. (REPL): Price and Financial Metrics
GET POWR RATINGS... FREE!
REPL Stock Price Chart Interactive Chart >
REPL Price/Volume Stats
|Current price||$32.64||52-week high||$54.85|
|Prev. close||$31.26||52-week low||$20.40|
|Day high||$32.64||Avg. volume||336,586|
|50-day MA||$32.28||Dividend yield||N/A|
|200-day MA||$35.75||Market Cap||1.53B|
Replimune Group, Inc. (REPL) Company Bio
Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer. It is developing various proprietary products intended to enhance the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The company was founded in 2015 is based in Abingdon, the United Kingdom.
Most Popular Stories View All
REPL Latest News Stream
|Loading, please wait...|
REPL Latest Social Stream
View Full REPL Social Stream
Latest REPL News From Around the Web
Below are the latest news stories about Replimune Group Inc that investors may wish to consider to help them evaluate REPL as an investment opportunity.
It''s been a feast for bears operating on an hourly timeframe, as repl has now gone down 8 of the past 10 hours. The post Replimune Group Inc (REPL): Price Now Near $30.17; Daily Chart Shows Downtrend on 50 Day Basis appeared first on ETF Daily News .
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Updated complete and durable response data in RP1 (vusolimogene oderparepvec) skin cancer cohorts support the ongoing registration directed development programs in CSCC and anti-PD-1 failed melanoma, with full accrual for both programs expected in mid-2022
WOBURN, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:
WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that Robert Coffin, Ph.D., President and Chief Research & Development Officer of Replimune, will participate in a panel titled Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors at the William Blair Biotech Focus Conference 2021 taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET.
REPL Price Returns